Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Diagnosis and prediction of precursor states in multiple myeloma using cell-free chromatin

Noa Omer Vilk, Vladimir Vainstein, Nadav Hermoni et al. Nov 03, 2025 pp. 3948-3948 10.1182/blood-2025-3948

Abstract Multiple myeloma (MM) is a hematological malignancy that, in many cases, is preceded by monoclonal gammopathy of undetermined signi...

Phosphatidylcholine synthesis inhibition diminishes ASXL1 and DNMT3a mutation driven clonal hematopoiesis

Brandon Gheller, Olivia Mitchell, Serine Avagyan et al. Nov 03, 2025 pp. 973-973 10.1182/blood-2025-973

Abstract The acquisition of somatic mutations that increase the competitive potential of hematopoietic stem and progenitor cell (HSPC) clone...

Clinical outcomes up to 4 years of once-weekly efanesoctocog alfa prophylaxis in previously treated adults, adolescents, and children with severe hemophilia A: Interim analysis of the Phase 3 XTEND-ed long-term extension study

Sophie Susen, Anthony Chan, Pratima Chowdary et al. Nov 03, 2025 pp. 539-539 10.1182/blood-2025-539

Abstract Introduction Efanesoctocog alfa is a first-in-class high-sustained factor VIII (FVIII) replacement therapy designed to decouple rec...

Paquinimod regulate megakaryocyte function by restoring mitochondrial oxidative phosphorylation in acute myeloid leukemia

Meng-Yu Xiao, Jing-Li Han, Jian-Ying Zhou et al. Nov 03, 2025 pp. 3021-3021 10.1182/blood-2025-3021

Abstract Introduction A malignant inflammatory microenvironment exists in acute myeloid leukemia (AML), and many inflammatory molecules affe...

A novel VWF mutation associated with macrothrombocytopenia, cytoskeletal defects, and distinct functional abnormalities: A case report

Ekaterina Balaian, Marko Barovic, Thomas Thiele et al. Nov 03, 2025 pp. 4861-4861 10.1182/blood-2025-4861

Abstract Background: von Willebrand disease type 2B (vWD 2B) is a rare inherited bleeding disorder characterized by gain-of-function mutatio...

An interactive database containing all known variants in ADAMTS13 yields new insight into the genetic variation and protein changes underlying congenital TTP

Matthew Carter, Imogen Buckle, Stephen Perkins et al. Nov 03, 2025 pp. 4869-4869 10.1182/blood-2025-4869

Abstract Introduction A disintegrin and metalloprotease with a thrombospondin type 1 motif, member 13 (ADAMTS13) is encoded by a 45kb gene o...

Disparities in venous thromboembolism management in patients with sickle cell disease: A nationwide inpatient sample study

Ashish Sharma, Angad Tiwari, Harendra Kumar et al. Nov 03, 2025 pp. 2974-2974 10.1182/blood-2025-2974

Abstract Background: Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is a substantial b...

Glofitamab combined with salvage therapy for relapsed or refractory aggressive B-cell lymphomas: Efficacy and safety in a real-world prospective observational study

Jin Zhou, Qian Wang, Tao You et al. Nov 03, 2025 pp. 7267-7267 10.1182/blood-2025-7267

Abstract Background: Glofitamab, a CD20×CD3 bispecific antibody, has shown remarkable efficacy in relapsed or refractory (R/R) aggressive B-...

β‑hydroxybutyrate metabolism enhances CAR T cell function via transcriptional and epigenetic reprogramming

Shan Liu, Puneeth Guruprasad, Ranjani Ramasubramanian et al. Nov 03, 2025 pp. 5903-5903 10.1182/blood-2025-5903

Abstract Introduction. The impact of patient (pt) lifestyle, particularly diet, on chimeric antigen receptor (CAR) T cell therapy remains po...

Healthcare Providers' knowledge and attitudes toward venous thromboembolism prophylaxis in multiple myeloma: A cross-sectional survey

Ghasoub Rola, Maria Benkhadra, Anas Hamad et al. Nov 03, 2025 pp. 6348-6348 10.1182/blood-2025-6348

Abstract Background: Venous thromboembolism (VTE) remains a major complication in multiple myeloma (MM), despite the recommended predictive...

Feasibility and impact of rapid newborn screening for sickle cell disease in Tanzania: Results from the tabora region pilot program (SickleCare)

Samwel Amin, Sebato Owino, Alan Anderson et al. Nov 03, 2025 pp. 6158-6158 10.1182/blood-2025-6158

Abstract Background: Tanzania bears a substantial burden of sickle cell disease (SCD), with an estimated 11,000 affected...

Indole-related metabolites suppress the anti-tumor function of CD8+ T cells in the bone marrow microenvironment of multiple myeloma

Yueyi An, Huixing Zhou, Xiaoyun Jin et al. Nov 03, 2025 pp. 3933-3933 10.1182/blood-2025-3933

Abstract Multiple myeloma (MM), the second most common hematologic malignancy, presents significant clinical challenges due to its relapsing...

CRISPR-ko screen identifies RARα inhibition as a strategy to increase CD38 expression in multiple myeloma and potentiate anti-CD38 therapy.

Laura Alibert, Sara scaramuzzino, Camille Soun et al. Nov 03, 2025 pp. 2146-2146 10.1182/blood-2025-2146

Abstract The monoclonal antibody (mAb) Daratumumab (Dara) targets CD38 to trigger cytotoxicity against myeloma cells. Dara achieves good res...

HIT or miss?: Long-term outcomes of direct thrombin inhibitors vs fondaparinux use in heparin-induced thrombocytopenia

Isuru Karunatillaka, Aparna Manoj, Sahan Senaratna et al. Nov 03, 2025 pp. 3114-3114 10.1182/blood-2025-3114

Abstract Background: Heparin-induced thrombocytopenia (HIT) is a rare but serious immune-mediated complication of heparin therapy characteriz...

A novel random survival forest model for adult NPM1-mutated Acute Myeloid Leukemia patients

Yiyi Yao, Lijie Wang, Xucan Lou et al. Nov 03, 2025 pp. 6134-6134 10.1182/blood-2025-6134

Abstract Background: NPM1-mutated acute myeloid leukemia (AML) is the most common molecular subtype in adult AML, comprising 30-35% of cases...

Curcumin and resveratrol sensitizes TP53 mutant acute myeloid leukemia (AML) cell lines to venetoclax-induced apoptosis

Merielle William, Prashant Trikha, Dmitriy Ovcharenko et al. Nov 03, 2025 pp. 6793-6793 10.1182/blood-2025-6793

Abstract While venetoclax-based regimens have significantly improved outcomes for many patients with acute myeloid leukemia (AML), those wit...

Heme-regulated eIF2α (HRI) is required during iron restriction to alleviate ß-thalassemia via mTORC1 inhibition, autophagy activation, and suppression of protein synthesis, contributing to clearance of toxic free α-globin

Alfonso Fernandez, Georgios Christakopoulos, Michael Dudley et al. Nov 03, 2025 pp. 728-728 10.1182/blood-2025-728

Abstract In β-thalassemia, hepcidin deficiency and chronic red blood cell (RBC) transfusions cause iron overload leading to multi-organ dama...

*pediatric transplant data from a center in a remote area in interior sindh, Pakistan*

Dr Asghar Ali, Muhammad Sarwar, Dr Hafiz Muhammad Nadeem Arain et al. Nov 03, 2025 pp. 7727-7727 10.1182/blood-2025-7727

Abstract Background: The Gambat Institute of Medical Sciences (GIMS), located in a remote region of interior Sindh, is only public-sector fa...

A randomized, multicenter trial of shorter durations of hypomethylating agents in lower-risk Myelodysplastic Syndromes

Ian Bouligny, Hetty Carraway, Mikkael Sekeres et al. Nov 03, 2025 pp. 487-487 10.1182/blood-2025-487

Abstract Background In higher-risk myelodysplastic syndromes (MDS), the standard doses of hypomethylating agents are azacitidine 75 mg/m2 fo...

CTD402: Allogeneic CAR-t manufacturing that overcomes donor- & process-derived variation with robust clinical activity

Xiaojing Zhang, Liping Zhu, Mengyao Wang et al. Nov 03, 2025 pp. 4180-4180 10.1182/blood-2025-4180

Abstract Background: Allogeneic CAR-T cell therapies offer key advantages over autologous approaches, including simplified manufacturing log...

Treatment funding source and educational level are important prognostic factors for patients with diffuse large B-cell lymphoma in the state of São paulo, Brazil: Analysis of a large real-world data.

Diego Clé, Rafael Gaiolla, Nelson Correa-Netto et al. Nov 03, 2025 pp. 6280-6280 10.1182/blood-2025-6280

Abstract Introduction: Diffuse large B-cell lymphoma (DLBCL) is among the ten most prevalent cancers in Brazil. Although the country has num...

Novel von willebrand factor targeting thrombolytic TGD001 is safe and well tolerated in a phase 1 first-in-human trial

Marie Scully, Spero Cataland, Paul Coppo et al. Nov 03, 2025 pp. 849-849 10.1182/blood-2025-849

Abstract Introduction TGD001 is a novel thrombolytic fusion protein that binds with high affinity to von Willebrand factor (VWF) for targete...

Impact of sequencing of CART vs bi-specific antibody on survival in relapsed/refractory large B-cell lymphoma: An analysis from the ABC consortium

Max Kelsten, Colin Thomas, Yun Kyoung Tiger et al. Nov 03, 2025 pp. 398-398 10.1182/blood-2025-398

Abstract Background: CART and bispecific antibodies (BsAb) are both effective treatments for patients (pts) with relapse...

The m5C-binding protein YB-1 modulates proteasome inhibitors resistance in multiple myeloma via epigenetic modification

Qiqi Shen, Xi Huang, Shunnan Yao et al. Nov 03, 2025 pp. 5700-5700 10.1182/blood-2025-5700

Abstract Multiple myeloma (MM) is a malignant proliferative disorder of plasma cells, and resistance to proteasome inhibitors (PIs) represen...

Imaging flow cytometry for detection of red blood cell inclusions: A quantitative approach to assess splenic filtration function in sickle cell disease

Cesar Rueda Rios, Miya Lu, Kristina Hanson et al. Nov 03, 2025 pp. 1188-1188 10.1182/blood-2025-1188

Abstract Introduction. The spleen plays a critical role in maintaining red blood cell (RBC) homeostasis by removing intracellular inclusions...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page